Queen's University | Member Profile | Leading Edge Only

Background
Innovations

Field of Expertise

Commercial Development

Expertise

20+ years in biopharma development and licensing

Published

Healthcare & Pharmaceuticals
Novel Antioxidant Peptides
We have granted US IP on novel human breast milk peptides with antioxidant properties. These peptides were selected from mother's breast milk based upon potency in ORAC tests.

By
Queen's University

Reference Number  
05346
Last Update  
 Jan 08, 2019

Published

Healthcare & Pharmaceuticals
Treatment for Bone Health
Glucosamine analog showed benefits on maintaining/improving bone health in multiple models of arthritis and osteoporosis. Effects similar or better than existing Rx products

By
Queen's University

Reference Number  
05399
Last Update  
 Mar 07, 2019

Published

Healthcare & Pharmaceuticals
VWD and Hemophilia Therapy
Novel recombinant proteins based on ancestral sequence reconstruction with higher specific activity than human vWF

By
Queen’s University

Reference Number  
07175
Last Update  
 Jul 20, 2021

Published

Healthcare & Pharmaceuticals
Actin-Inhibitors
Targeting actin with inhibitory small molecules could complement existing cytotoxic therapies and protect cancer patients from cancer progression to metastatic disease

By
Queen’s University

Reference Number  
07176
Last Update  
 Jul 20, 2021

Published

Healthcare & Pharmaceuticals
Selective Cyp26 Antagonists
Cyp26 inhibitor compounds treat diseases such as psoriasis, while avoiding retinoid related side effects

By
Queen’s University

Reference Number  
07177
Last Update  
 Jul 20, 2021

Published

Healthcare & Pharmaceuticals
Novel NEN Diagnostic
A microRNA‑based hierarchical classifier which can both identify and sub-classify neuroendocrine neoplasms (NENs)

By
Queen’s University

Reference Number  
07209
Last Update  
 Jul 20, 2021